Why is Sun Pharma betting $11.75B on a struggling US drugmaker?

In one of the biggest outbound acquisitions ever attempted by an Indian company, Sun Pharmaceutical Industries has decided to buy Organon & Co. for $14 a share in an all-cash deal valued at US$11.8 billion (approx. $16.4 billion)

The logic of the deal is easy to state and harder to execute as Sun is not buying a fast-growing asset, but a scaled global platform with meaningful cash flow, a large commercial footprint and a huge debt load.

Sun is planning to expand in women’s health, biosimilars and innovative medicines, while Organon brings more than 70 products across women’s health and general medicines in 140 countries.

A pricey answer to a strategic problem

For Sun Pharma, the transaction is as much about strategy as scale.

The company has long been a generics heavyweight, but this deal gives it a sharper global identity in higher-value categories.

In its statement, Sun said the combined business would generate about US$12.4 billion (approx. $17.3 billion) in revenue and rank among the top 25 global pharmaceutical companies.

The acquisition would make it a top-three player in global women’s health, while also creating a biosimilars platform that would place it seventh globally.

It also said the mix would lift the share of innovative medicines to 27% of revenue, which signaled a more diversified profile than Sun’s traditional portfolio.

That is the bull case. The bear case is that Sun is paying full price for a business that still carries baggage.

Organon was spun off from Merck in 2021 and has not been a growth story since.

The acquisition is being funded through available cash and committed bank financing, which makes leverage and integration central to the investment case.

The deal is approved by both boards, but still needs regulatory clearances and Organon shareholder approval, with closing expected in early 2027.

Also read: HSBC downgrades Indian equities to Underweight as oil surge hits markets

Organon’s value lies in cash flow

Organon’s appeal is easier to understand as the company reported 2025 revenue of US$6.2 billion (approx. $8.6 billion) and adjusted EBITDA of US$1.9 billion (approx. $2.7 billion), and said it expected roughly the same scale in 2026.

It also carried $8.6 billion US$8.6 billion (approx. $12 billion) of debt and US$574 million (approx. $800.2 million) in cash at the end of 2025, a balance sheet that explains why the equity story has looked so subdued despite the size of the franchise.

In simple words, Organon is not being bought for momentum, but for operating cash generation, global distribution and a portfolio that still has strategic relevance.

That makes this less of a turnaround bet than a balance-sheet-and-strategy trade.

Organon’s own results showed revenue down 3% in 2025 and guided for approximately flat revenue and adjusted EBITDA in 2026.

The company’s women’s health and fertility businesses remain important, but the broader picture is mixed, with pressure in established brands and continuing competitive and pricing challenges.

Sun is looking to deepen its exposure to the US market even as it grapples with soft sales there, which adds another layer to the rationale for the purchase.